Literature DB >> 30925286

Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination.

Dunwan Zhu1, Chunyan Hu1, Fan Fan1, Yu Qin1, Chenlu Huang1, Zhiming Zhang1, Lu Lu2, Hai Wang1, Hongfan Sun1, Xigang Leng1, Chun Wang3, Deling Kong4, Linhua Zhang5.   

Abstract

Exploiting Toll-like receptor (TLR) agonists or their certain combinations can enhance the immune potency of subunit vaccine. Nevertheless, the design of co-delivery systems which can act in a synergistic and spatio-temporal way to achieve effective and durable specific immune response is still challenging. Here we fabricated mannose-functionalized lipid-hybrid polymersomes (MAN-IMO-PS) for co-delivery of ovalbumin antigen both inside the inner core and outside the lipid layer, TLR7/8 agonist imiquimod within the hydrophobic membrane, TLR4 agonist monophosphoryl lipid A in the lipid layer as programmed nanovaccine to synergistically activate immune responses for improving vaccine efficacy. After efficiently internalized by dendritic cells via mannose targeting and TLR4 ligating, MAN-IMO-PS significantly enhanced cross-presentation and cytokine production. In addition, MAN-IMO-PS showed depot effect at the injection site and enhanced migration to draining lymph nodes. Mice immunized with MAN-IMO-PS elicited greater lymphocyte activation, CD4+ and CD8+ T cell response, effector cytokines secretion, and induced Th-1 biased humoral responses. More importantly, prophylactic vaccination by MAN-IMO-PS significantly delayed tumor occurrence, suppressed tumor growth with prolonged survival, and achieved long-term immune effect. The present study demonstrates a rationally designed nanovaccine for combining antigen, different TLR agonists, and targeting moiety in a programmed manner to induce synergistic antitumor immune response.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Antigen delivery; Cancer vaccine; Imiquimod; Lipid-hybrid polymersomes; Mannose-receptor targeting; Monophosphoryl lipid A

Year:  2019        PMID: 30925286     DOI: 10.1016/j.biomaterials.2019.03.012

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  10 in total

Review 1.  The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy.

Authors:  Lingling Huang; Xiaoyan Ge; Yang Liu; Hui Li; Zhiyue Zhang
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

Review 2.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

Review 3.  Cross-presentation of exogenous antigens on MHC I molecules.

Authors:  Jeff D Colbert; Freidrich M Cruz; Kenneth L Rock
Journal:  Curr Opin Immunol       Date:  2020-01-09       Impact factor: 7.486

Review 4.  Polymeric nanoparticle vaccines to combat emerging and pandemic threats.

Authors:  David Wibowo; Sytze H T Jorritsma; Zennia Jean Gonzaga; Benjamin Evert; Shuxiong Chen; Bernd H A Rehm
Journal:  Biomaterials       Date:  2020-12-10       Impact factor: 12.479

Review 5.  Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development.

Authors:  Jie Liang; Xiao Zhao
Journal:  Cancer Biol Med       Date:  2021-05-12       Impact factor: 4.248

Review 6.  Fabrication of subunit nanovaccines by physical interaction.

Authors:  HaoLin Chen; Hong Liu; LiXin Liu; YongMing Chen
Journal:  Sci China Technol Sci       Date:  2022-04-08

7.  Mannose Receptor-Mediated Carbon Nanotubes as an Antigen Delivery System to Enhance Immune Response Both In Vitro and In Vivo.

Authors:  Haibo Feng; Yangyang Feng; Lang Lin; Daiyan Wu; Qianqian Liu; Hangyu Li; Xinnan Zhang; Sheng Li; Feng Tang; Ziwei Liu; Linzi Zhang
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

Review 8.  In vivo fate and intracellular trafficking of vaccine delivery systems.

Authors:  Jaiwoo Lee; Dongyoon Kim; Junho Byun; Yina Wu; Jinwon Park; Yu-Kyoung Oh
Journal:  Adv Drug Deliv Rev       Date:  2022-05-10       Impact factor: 17.873

Review 9.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

10.  Essential Role of Host Double-Stranded DNA Released from Dying Cells by Cationic Liposomes for Mucosal Adjuvanticity.

Authors:  Rui Tada; Akihiro Ohshima; Yuya Tanazawa; Akari Ohmi; Saeko Takahashi; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki; Yoichi Negishi
Journal:  Vaccines (Basel)       Date:  2019-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.